Guggenheim Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $80

Benzinga · 4d ago
Guggenheim analyst Delma Caiati initiates coverage on LB Pharmaceuticals (NASDAQ:LBRX) with a Buy rating and announces Price Target of $80.